Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor
…, P Chène, K Shoemaker, A De Pover, D Menezes… - Molecular cancer …, 2012 - AACR
Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound,
we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors from different …
we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors from different …
Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer
…, K Huh, E Iwanowicz, X Xin, D Menezes… - ACS medicinal …, 2011 - ACS Publications
Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation
of this signaling pathway in a wide variety of human cancers. Herein we describe the …
of this signaling pathway in a wide variety of human cancers. Herein we describe the …
Is the proximal femoral nail a suitable implant for treatment of all trochanteric fractures?
DFA Menezes, A Gamulin… - … and Related Research …, 2005 - journals.lww.com
We reviewed 155 consecutive patients who were treated with a proximal femoral nail from
1997 to 2001 to determine the rate of implant specific complications. Results were stratified …
1997 to 2001 to determine the rate of implant specific complications. Results were stratified …
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
…, G Bhagat, R Nandakumar, D Menezes… - Blood, The Journal …, 2021 - ashpublications.org
Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We
demonstrated in vitro synergism between histone deacetylase inhibitors and DNA …
demonstrated in vitro synergism between histone deacetylase inhibitors and DNA …
Design, structure− activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase …
…, RL Warne, CC Heise, D Menezes… - Journal of medicinal …, 2009 - ACS Publications
The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature
formation and maintenance, as well as tumor progression and metastasis, has been a …
formation and maintenance, as well as tumor progression and metastasis, has been a …
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
…, CL Beach, A Risueño, DL Menezes… - Blood, The Journal …, 2022 - ashpublications.org
Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in
remission after intensive chemotherapy is predictive of early relapse and poor survival. …
remission after intensive chemotherapy is predictive of early relapse and poor survival. …
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
…, B Cheng, A Risueño, D Menezes… - Blood, The Journal …, 2019 - ashpublications.org
The peripheral T-cell lymphomas (PTCLs) are uniquely sensitive to epigenetic modifiers.
Based on the synergism between histone deacetylase inhibitors and hypomethylating agents …
Based on the synergism between histone deacetylase inhibitors and hypomethylating agents …
A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function
DL Menezes, J Holt, Y Tang, J Feng, P Barsanti… - Molecular Cancer …, 2015 - AACR
Mechanisms to maintain genomic integrity are essential for cells to remain viable. Not
surprisingly, disruption of key DNA damage response pathway factors, such as ataxia …
surprisingly, disruption of key DNA damage response pathway factors, such as ataxia …
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial
…, J Poon, M Simcock, M Patturajan, D Menezes… - Blood …, 2021 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for
most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling the …
most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling the …
The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo
DL Menezes, P Taverna, MR Jensen, T Abrams… - Molecular cancer …, 2012 - AACR
A novel oral Hsp90 inhibitor, NVP-HSP990, has been developed and characterized in vitro
and in vivo. In vitro, NVP-HSP990 exhibits single digit nanomolar IC 50 values on three of the …
and in vivo. In vitro, NVP-HSP990 exhibits single digit nanomolar IC 50 values on three of the …